Immune System Modulation and Outcome in High-risk Cutaneous Squamous Cell Carcinoma Treated With Surgery and Radiotherapy: a Prospective Study
The study sponsored by Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia aims to elucidate the immune modulation effects of adjuvant radiotherapy in patients with high-risk cSCC. Given the increasing incidence of skin cancers and the potential for improved patient outcomes through enhanced understanding of immune responses, this research could inform future therapeutic strategies and positioning in the oncology market. The findings may also provide insights into patient stratification for immunotherapy approaches, potentially enhancing the competitive landscape against existing treatments. The study's outcomes could be pivotal for companies developing immunomodulatory therapies or combination treatments involving radiotherapy.
Indication: Squamous Cell Carcinoma of the Skin
Modality: RNA therapy
Target: Immune cell populations modulation during adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma (cSCC).
Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 25, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Immune cell populations modulation during adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma (cSCC).
View original source fields
Condition raw: Squamous Cell Carcinoma of the Skin
Condition normalized: Squamous Cell Carcinoma of the Skin
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: Immune cell populations modulation during adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma (cSCC).
Target normalized: Immune cell populations modulation during adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma (cSCC).